Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332483 | 0.97 | KDM4E (0.50) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL21111516 | 0.97 | KDM4E (0.50) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL4965925 | 0.95 | — | — | |
| SCHEMBL18874871 | 0.91 | CA3 (0.45) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL3174690 | 0.86 | KDM4E (0.50) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL2720594 | 0.84 | PAOX (0.44) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL10656502 | 0.84 | PAOX (0.44) | KDM4EMAPK1HIF1AMEN1KMT2A | |
| SCHEMBL21997079 | 0.84 | ALDH1A1 (0.41) | KDM4EMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL1863794 | 0.83 | — | — | |
| SCHEMBL5569558 | 0.83 | KDM4E (0.55) | KDM4EMAPK1HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676434-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3209651-B9 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2020069105-A1 | DEGRADERS OF WEE1 KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-3209651-B1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190225583-A1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| US-10266491-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3390382-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-21 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329901-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2421849-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Theravance, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421538-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2010123870-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123766-A1 | DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885MAPK1 4884/4885HIF1A 4351/4885 |
| US-10266491-B2 | Carbazole derivatives | BTK, SYK, JAK2 | KDM4E 1490/4885MAPK1 304/4885HIF1A 4625/4885 |
| US-10676434-B2 | Carbazole derivatives | BTK, SYK, JAK2 | KDM4E 1307/4885MAPK1 340/4885HIF1A 4663/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885MAPK1 4884/4885HIF1A 4351/4885 |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | KDM4E 1490/4885MAPK1 304/4885HIF1A 4625/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885MAPK1 4884/4885HIF1A 4351/4885 |
| US-11053197-B2 | Carbazole derivatives | BTK, SYK, JAK2 | KDM4E 1307/4885MAPK1 340/4885HIF1A 4663/4885 |
| US-20190225583-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | KDM4E 1307/4885MAPK1 340/4885HIF1A 4663/4885 |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | KDM4E 1307/4885MAPK1 340/4885HIF1A 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.